4phc - Revision history

OCA at 00:43, 28 December 2023

2023-12-28T00:43:54Z

← Older revision		Revision as of 00:43, 28 December 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PHC FirstGlance]. <br>		<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PHC FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.844Å</td></tr>
			<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [https://pdbe.org/4phc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [https://www.ebi.ac.uk/pdbsum/4phc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [https://pdbe.org/4phc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [https://www.ebi.ac.uk/pdbsum/4phc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>
	</table>		</table>

OCA at 13:02, 1 February 2023

2023-02-01T13:02:50Z

← Older revision		Revision as of 13:02, 1 February 2023
Line 3:		Line 3:
	<StructureSection load='4phc' size='340' side='right'caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>		<StructureSection load='4phc' size='340' side='right'caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4PHC FirstGlance]. <br>		<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PHC FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene~~></td></tr>~~		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>
	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HARS, HRS ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>~~		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [https://pdbe.org/4phc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [https://www.ebi.ac.uk/pdbsum/4phc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [~~http~~://pdbe.org/4phc PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4phc PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
	[~~[http~~://www.uniprot.org/uniprot/~~SYHC_HUMAN SYHC_HUMAN]~~] ~~Defects in HARS are a cause of~~ Usher syndrome type ~~3B (USH3B) [MIM:~~[~~http~~://~~omim~~.org/~~entry~~/~~614504 614504]~~]~~. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have~~ the so-~~called~~ '~~Charles Bonnet syndrome~~,~~' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by~~ the ~~association~~ of ~~retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1~~ (~~USH1~~)~~, Usher syndrome type 2~~ (~~USH2~~) ~~and Usher syndrome type 3~~ (~~USH3~~). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.<ref>PMID:~~22279524~~</ref> Note=HARS mutations may be involved in peripheral neuropathy, a disease mainly characterized by distal motor and sensory dysfunction. Inherited peripheral neuropathies are clinically and genetically heterogeneous with variable age of onset and reduced penetrance associated with specific loci. HARS mutations may directly predispose patients to peripheral neuropathy or may modify a peripheral neuropathy phenotype by contributing to the genetic and environmental load in a given patient (PubMed:~~22930593).~~		[https://www.uniprot.org/uniprot/HARS1_HUMAN HARS1_HUMAN] Usher syndrome type 3;Autosomal dominant Charcot-Marie-Tooth disease type 2W. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry.
			== Function ==
			[https://www.uniprot.org/uniprot/HARS1_HUMAN HARS1_HUMAN] Catalyzes the ATP-dependent ligation of histidine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (His-AMP) (PubMed:29235198). Plays a role in axon guidance (PubMed:26072516).<ref>PMID:26072516</ref> <ref>PMID:29235198</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 27:		Line 27:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Histidine--tRNA ligase]]~~		[[Category: Homo sapiens]]
	~~[[Category: Human~~]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Hol~~, W G.J~~]]		[[Category: Hol WGJ]]
	[[Category: Koh~~, C Y]]~~		[[Category: Koh CY]]
	~~[[Category: Schueren, W J.de van der~~]]		[[Category: Wetzel AB]]
	[[Category: Wetzel~~, A B~~]]		[[Category: De van der Schueren WJ]]
	[[Category: ~~Aar]]~~
	~~[[Category: Aminoacyl-trna synthetase]]~~
	~~[[Category: Cytoplasmic]]~~
	~~[[Category: Hisr]]~~
	~~[[Category: Ligase]]~~
	~~[[Category: Nucleotide binding]]~~
	~~[[Category: Protein-substrate complex]]~~
	~~[[Category: Rossmann-fold]]~~
	~~[[Category: Translation~~]]

OCA at 15:36, 11 December 2019

2019-12-11T15:36:57Z

← Older revision		Revision as of 15:36, 11 December 2019
Line 1:		Line 1:

	==Crystal Structure of a human cytosolic histidyl-tRNA synthetase, histidine-bound==		==Crystal Structure of a human cytosolic histidyl-tRNA synthetase, histidine-bound==
	<StructureSection load='4phc' size='340' side='right' caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>		<StructureSection load='4phc' size='340' side='right'caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHC FirstGlance]. <br>		<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHC FirstGlance]. <br>
Line 20:		Line 20:
	</div>		</div>
	<div class="pdbe-citations 4phc" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4phc" style="background-color:#fffaf0;"></div>

			==See Also==
			*[[Aminoacyl tRNA synthetase 3D structures\|Aminoacyl tRNA synthetase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 26:		Line 29:
	[[Category: Histidine--tRNA ligase]]		[[Category: Histidine--tRNA ligase]]
	[[Category: Human]]		[[Category: Human]]
			[[Category: Large Structures]]
	[[Category: Hol, W G.J]]		[[Category: Hol, W G.J]]
	[[Category: Koh, C Y]]		[[Category: Koh, C Y]]

OCA at 08:40, 22 November 2017

2017-11-22T08:40:52Z

← Older revision		Revision as of 08:40, 22 November 2017
Line 3:		Line 3:
	<StructureSection load='4phc' size='340' side='right' caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>		<StructureSection load='4phc' size='340' side='right' caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHC FirstGlance]. <br>		<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHC FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>
			<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HARS, HRS ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [http://pdbe.org/4phc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [http://www.ebi.ac.uk/pdbsum/4phc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [http://pdbe.org/4phc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [http://www.ebi.ac.uk/pdbsum/4phc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>
Line 24:		Line 25:
	</StructureSection>		</StructureSection>
	[[Category: Histidine--tRNA ligase]]		[[Category: Histidine--tRNA ligase]]
			[[Category: Human]]
	[[Category: Hol, W G.J]]		[[Category: Hol, W G.J]]
	[[Category: Koh, C Y]]		[[Category: Koh, C Y]]
Line 32:		Line 34:
	[[Category: Cytoplasmic]]		[[Category: Cytoplasmic]]
	[[Category: Hisr]]		[[Category: Hisr]]
	~~[[Category: Human]]~~
	[[Category: Ligase]]		[[Category: Ligase]]
	[[Category: Nucleotide binding]]		[[Category: Nucleotide binding]]

OCA at 17:26, 9 March 2017

2017-03-09T17:26:32Z

← Older revision		Revision as of 17:26, 9 March 2017
Line 1:		Line 1:

	==Crystal Structure of a human cytosolic histidyl-tRNA synthetase, histidine-bound==		==Crystal Structure of a human cytosolic histidyl-tRNA synthetase, histidine-bound==
	<StructureSection load='4phc' size='340' side='right' caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>		<StructureSection load='4phc' size='340' side='right' caption='[[4phc]], [[Resolution\|resolution]] 2.84Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [http://www.ebi.ac.uk/pdbsum/4phc PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [http://pdbe.org/4phc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [http://www.ebi.ac.uk/pdbsum/4phc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4phc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 17:		Line 18:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
			<div class="pdbe-citations 4phc" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 06:57, 3 June 2015

2015-06-03T06:57:50Z

← Older revision		Revision as of 06:57, 3 June 2015
Line 9:		Line 9:
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/SYHC_HUMAN SYHC_HUMAN]] Defects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:[http://omim.org/entry/614504 614504]]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.<ref>PMID:22279524</ref> Note=HARS mutations may be involved in peripheral neuropathy, a disease mainly characterized by distal motor and sensory dysfunction. Inherited peripheral neuropathies are clinically and genetically heterogeneous with variable age of onset and reduced penetrance associated with specific loci. HARS mutations may directly predispose patients to peripheral neuropathy or may modify a peripheral neuropathy phenotype by contributing to the genetic and environmental load in a given patient (PubMed:22930593).		[[http://www.uniprot.org/uniprot/SYHC_HUMAN SYHC_HUMAN]] Defects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:[http://omim.org/entry/614504 614504]]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.<ref>PMID:22279524</ref> Note=HARS mutations may be involved in peripheral neuropathy, a disease mainly characterized by distal motor and sensory dysfunction. Inherited peripheral neuropathies are clinically and genetically heterogeneous with variable age of onset and reduced penetrance associated with specific loci. HARS mutations may directly predispose patients to peripheral neuropathy or may modify a peripheral neuropathy phenotype by contributing to the genetic and environmental load in a given patient (PubMed:22930593).
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			As part of a project aimed at obtaining selective inhibitors and drug-like compounds targeting tRNA synthetases from trypanosomatids, we have elucidated the crystal structure of human cytosolic histidyl-tRNA synthetase (Hs-cHisRS) in complex with histidine in order to be able to compare human and parasite enzymes. The resultant structure of Hs-cHisRS*His represents the substrate-bound state (H-state) of the enzyme. It provides an interesting opportunity to compare with ligand-free and imidazole-bound structures Hs-cHisRS published recently, both of which represent the ligand-free state (F-state) of the enzyme. The H-state Hs-cHisRS undergoes conformational changes in active site residues and several conserved motif of HisRS, compared to F-state structures. The histidine forms eight hydrogen bonds with HisRS of which six engage the amino and carboxylate groups of this amino acid. The availability of published imidazole-bound structure provides a unique opportunity to dissect the structural roles of individual chemical groups of histidine. The analysis revealed the importance of the amino and carboxylate groups, of the histidine in leading to these dramatic conformational changes of the H-state. Further, comparison with previously published trypanosomatid HisRS structures reveals a pocket in the F-state of the parasite enzyme that may provide opportunities for developing specific inhibitors of Trypanosoma brucei HisRS.

			Comparison of histidine recognition in human and trypanosomatid histidyl-tRNA synthetases.,Koh CY, Wetzel AB, de van der Schueren WJ, Hol WG Biochimie. 2014 Nov;106:111-20. doi: 10.1016/j.biochi.2014.08.005. Epub 2014 Aug , 20. PMID:25151410<ref>PMID:25151410</ref>

			From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
			</div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 07:45, 25 December 2014

2014-12-25T07:45:08Z

← Older revision		Revision as of 07:45, 25 December 2014
Line 3:		Line 3:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHC FirstGlance]. <br>		<table><tr><td colspan='2'>[[4phc]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PHC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PHC FirstGlance]. <br>
	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene><br>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=HIS:HISTIDINE'>HIS</scene></td></tr>
	<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Histidine--tRNA_ligase Histidine--tRNA ligase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=6.1.1.21 6.1.1.21] </span></td></tr>
	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [http://www.ebi.ac.uk/pdbsum/4phc PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4phc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4phc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4phc RCSB], [http://www.ebi.ac.uk/pdbsum/4phc PDBsum]</span></td></tr>
	<table>		</table>
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/SYHC_HUMAN SYHC_HUMAN]] Defects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:[http://omim.org/entry/614504 614504]]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.<ref>PMID:22279524</ref> Note=HARS mutations may be involved in peripheral neuropathy, a disease mainly characterized by distal motor and sensory dysfunction. Inherited peripheral neuropathies are clinically and genetically heterogeneous with variable age of onset and reduced penetrance associated with specific loci. HARS mutations may directly predispose patients to peripheral neuropathy or may modify a peripheral neuropathy phenotype by contributing to the genetic and environmental load in a given patient (PubMed:22930593).		[[http://www.uniprot.org/uniprot/SYHC_HUMAN SYHC_HUMAN]] Defects in HARS are a cause of Usher syndrome type 3B (USH3B) [MIM:[http://omim.org/entry/614504 614504]]. USH3B is a syndrome characterized by progressive vision and hearing loss during early childhood. Some patients have the so-called 'Charles Bonnet syndrome,' involving decreased visual acuity and vivid visual hallucinations. USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual, progressive hearing loss, variable vestibular dysfunction, and onset of retinitis pigmentosa symptoms, including nyctalopia, constriction of the visual fields, and loss of central visual acuity, usually by the second decade of life.<ref>PMID:22279524</ref> Note=HARS mutations may be involved in peripheral neuropathy, a disease mainly characterized by distal motor and sensory dysfunction. Inherited peripheral neuropathies are clinically and genetically heterogeneous with variable age of onset and reduced penetrance associated with specific loci. HARS mutations may directly predispose patients to peripheral neuropathy or may modify a peripheral neuropathy phenotype by contributing to the genetic and environmental load in a given patient (PubMed:22930593).
	~~== Function ==~~

	== References ==		== References ==
	<references/>		<references/>
Line 16:		Line 14:
	</StructureSection>		</StructureSection>
	[[Category: Histidine--tRNA ligase]]		[[Category: Histidine--tRNA ligase]]
	[[Category: Hol, W G.J.]]		[[Category: Hol, W G.J]]
	[[Category: Koh, C Y.]]		[[Category: Koh, C Y]]
	[[Category: Schueren, W J.de van der.]]		[[Category: Schueren, W J.de van der]]
	[[Category: Wetzel, A B.]]		[[Category: Wetzel, A B]]
	[[Category: Aar]]		[[Category: Aar]]
	[[Category: Aminoacyl-trna synthetase]]		[[Category: Aminoacyl-trna synthetase]]

OCA at 08:55, 27 August 2014

2014-08-27T08:55:14Z

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
+==Crystal Structure of a human cytosolic histidyl-tRNA synthetase, histidine-bound==
-The entry 4phc is ON HOLD  until Paper Publication
+== References ==
+<references/>
-Authors: Koh, C.Y., Wetzel, A.B., de van der Schueren, W.J., Hol, W.G.J.
+__TOC__
+</StructureSection>
-Description:
+[[Category: Histidine--tRNA ligase]]

OCA at 06:56, 30 July 2014

2014-07-30T06:56:20Z

← Older revision		Revision as of 06:56, 30 July 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 4phc is ON HOLD		The entry 4phc is ON HOLD until Paper Publication

	Authors: Koh, C.Y., Wetzel, A.B., de van der Schueren, W.J., Hol, W.G.J.		Authors: Koh, C.Y., Wetzel, A.B., de van der Schueren, W.J., Hol, W.G.J.

	Description:		Description:

OCA: Protected "4phc" [edit=sysop:move=sysop]

2014-05-14T07:08:14Z

Protected "4phc" [edit=sysop:move=sysop]

← Older revision	Revision as of 07:08, 14 May 2014
(No difference)